Selecting Criteria for the Diagnosis of "Diabetes Mellitus" C urrent advances in knowledge notwithstanding, the diagnosis of diabetes mellitus must continue to rely on blood glucose determinations. In most populations the distribution of blood glucose levels forms a continuum and thus forces an arbitrary selection of cutoff points for diagnostic standards. The varied nature of diabetes-its multisystem, insidious involvement and varying natural history-complicates the choice of clinical events to validate such decisions. Against this background, a committee sponsored by the National Diabetes Data Group of the National Institutes of Health has confronted the problem with the laudable goal of achieving a universal set of methods and standards for the diagnosis and classification of diabetes mellitus. 1 The resulting proposals, based on presently available data, must now be evaluated, contrasting their strengths and weaknesses with existing criteria, lest the uncritical adoption of yet another set of standards creates rather than eliminates misunderstanding, confusion, and further dogma surrounding the definition of diabetes mellitus. The rriain purpose of this editorial is to focus on considerations brought up but minimized in the NIH report rather than disagree with the proposed classification and criteria.
The area of greatest numerical impact is among the asymptomatic non-insulin-dependent hyperglycemic subjects, traditionally classified as having maturity-onset-type diabetes. The proposed NIH criteria divides the population whose blood glucose levels fall above normal into impaired glucose tolerance (IGT) and diabetic classes (with and without fasting hyperglycemia). The benefits of this change are psychological and socioeconomic and are gained through the avoidance of the label "diabetes" in the great majority of persons not having normal carbohydrate metabolism (criteria for normal glucose tolerance have not changed substantially).
The blood glucose levels adopted for the proposed NIH criteria are based in large measure on the characteristic blood glucose distributions in the Pima Indians. They differ in several respects from other groups with non-insulin-dependent diabetes, by having one of the world's highest prevalence rates of diabetes mellitus and a lower frequency of macrdvascular complications than seen in Caucasian populations. In Pimas above age 25 yr, a mathematical model of two overlapping Gausian distributions (bimodal model) adequately describes the plasma glucose levels both fasting and 2 h after an oral glucose load. Although such bimodality cannot be accepted uncritically for setting criteria, 2 the potential effects of applying the derived cutpoints can be subjected to testing to evaluate their utility. Applying the proposed levels would, in effect, reserve the term diabetes mellitus for persons with confirmed fasting hyperglycemia (two values ^ 140 mg/dl) and, in the absence of fasting hyperglycemia, for those with sustained, grossly elevated postglucose values in at least two glucose tolerance tests (two values, including the 2-h value ^ 200 mg/dl in both tests). Precise cross-sectional data characterizing the effect of this definition are not currently available. For a modified version of the criteria, 3 results from the population in Sudbury, Massachusetts, show that the exclusion of diabetic subjects with fasting normoglycemia (< 125 mg/dl) will result in at least a 50% reduction in the prevalence of diabetes (from 1.8% to 0.97%, including previously known diabetes). 2 The application of the new criteria should therefore result in a major redistribution of persons with abnormal glucose tolerance into a relatively rare category of "diabetes mellitus" and a large category of "impaired glucose tolerance (IGT)."
In chosing one set of criteria over others, 4 * 5 one must recognize the differing biologic, predictive, and prognostic properties of criteria. The reality is that criteria can have differing objectives; the evaluation of diagnostic standards must consider which functions are being emphasized as well as the appropriateness of the choice of the particular function as the objective of the criteria.
Considering possible prognostic properties, the proposed NIH criteria rely on evidence of the presence of microvascular disease rather than on mortality or morbidity rates from both macrovascular and microvascular disease, in order to designate blood glucose values indicating the presence of diabetes mellitus. Exclusive reliance on one aspect of the health risks to persons with abnormal carbohydrate metabolism will appear unduly restrictive to many people. Although microvascular disease is more specific for diabetes than macrovascular disease, the latter has a greater impact on the health of the non-insulin-dependent diabetic patient. Indeed, the evidence supporting the chosen glucose levels as the exclusive prognosticators of microvascular disease bears further review. Data from the Pima Indians indicate that retinopathy is associated with a wide spectrum of glucose levels, including persons in the proposed IGT range, or first mode (interpreted normal or nondiabetic), although greatly accentuated in the second mode. 6 Subsequent study of subjects in the original Whitehall study leads to a similar conclusion, that retinopathy occurs in subjects the investigators consider to have "normal" or "impaired" tolerance to glucose. 7 Conversely, patients can have insulin-dependent diabetes without developing clinically apparent microvascular disease for 20-40 yr. 8 ' 9 These findings suggest that narrowing the diagnosis of diabetes mellitus to a small subset of persons with gross and sustained glucose intolerance can be questioned when judged by the presence of microvascular disease alone. Moreover, the confining nature of the NIH definition will minimize the importance of macrovascular disease and increased mortality rates among persons with IGT. The potential psychologic and socioeconomic advantages of restricting the use of the label diabetes must be weighed against the reduction in care that will surely follow for the majority of individuals with abnormal glucose tolerance tests who will not now be considered by many as having an abnormality of potential prognostic significance. Although DIABETES CARE, VOL. 3 NO. 4, JULY-AUGUST 1980 progression to overt diabetes has been observed in from 10% to 70% of such individuals over a span of 8-14 yr, 1>2 weight reduction in the obese can materially reduce such progression. In contrast to the interpretation of the Pima Indian data based on bimodality, the NIH Diabetes Data Group did establish a class between normal and diabetes (as presently defined) to imply that individuals in this group should not be considered normal. Such individuals are at higher risk than the general population for developing overt diabetes. As stated in the NIH report, many studies of groups of subjects with IGT have shown an increased prevalence of arterial disease, electrocardiographic abnormalities, and death or increased susceptibility to atherosclerotic disease associated with other known risk factors. 1 ' 3 Impaired glucose tolerance developing in the pregnant woman (a state that normally raises postprandial blood glucose levels) is accepted as "diabetes" (gestational diabetes) by the NIH report because of the associated prognostic significance in terms of abnormal neonatal evepts. Progression of gestational diabetes to diabetes by the USPHS criteria occurs with a frequency of 60% over 15 yr. This illustrates how diagnostic criteria are modified based on another set of predictive properties. If the definition of diabetes is not based on prognosis in regard to progression or development of vascular disease but on biologic events that define emerging insulin insufficiency characteristic of diabetes, differing criteria would be employed. The acute insulin secretory response to intravenously administered glucose, which characterizes normal beta-cell function, disappears above a fasting plasma glucose of 115 mg/dl 10 ' 11 and could be another definition of diabetes. These examples underscore the various considerations that need to be kept in mind in a definition of criteria to differentiate normal from abnormal.
The American Diabetes Association has wisely restricted its endorsement of the proposed NIH criteria to an approval in principle only. Before their intended review in several years, it is incumbent on persons working in the field to identify and to address the issues involved. The fundamental choices referred to here should not preclude assessing other characteristics of the NIH criteria, including the proposed rpethodology. For example, the effect of the size and character of the glucose challenge, which is dealt with briefly in the NIH rationale, should be carefully considered in the jight of further data. This can have greater effects than heretofore appreciated when applied to potentially abnormal individuals, 12 that is, persons most in need of the diagnostic test.
The publication of the proposed NIH criteria provides a valuable service. Modification of these criteria already has been suggested by some, including members of the NIH working group. 3 They propose that diagnostic criteria for the oral glucose tolerance test (QGTT) should include an elevated level of fasting plasma glucose (>140 mg/dl), 3 a level that is generally accepted as diagnostic without performance of the OGTT. Whether or not the new NIH standards are finally adopted, their publication focuses attention on many of the unresolved problems that bear on the choice of diagnostic standards for diabetes mellitus. It is to be hoped that the initiative of the Data Group will also stimulate the collection of further data to resolve these problems. 
